(Stroke. 1997;28:2053-2059.)
© 1997 American Heart Association, Inc.
Articles |
From the Section of Neurosurgery, Department of Surgery, University of Chicago (Ill).
Correspondence to H. Zhang, MD, PhD, Deborah Research Institute, 20 Pine Mill Rd, Brown Mills, NJ 08015-1799. E-mail jzhang{at}cybernet.net
| Abstract |
|---|
|
|
|---|
Methods Rat basilar smooth muscle cells were isolated by an enzymatic method. [Ca2+]i mobilization in freshly isolated cells was monitored using fura 2 microfluorimetry.
Result Extracellular nucleotides produced a
concentration-dependent biphasic [Ca2+]i
response, a large transient peak followed by a slowly decaying plateau.
The potency of nucleotides to raise
[Ca2+]i was ATP
S
UDP
ATP
UDP
TTP,
indicating that P2u receptors were expressed in the rat
basilar smooth muscle cells. The effect of UTP to release
Ca2+ from internal stores was reduced by pertussis toxin,
by the phospholipase C inhibitor 2-nitro-4-carboxyphenyl
N,N-diphenylcarbamate, and by the Ca2+-pump
inhibitor thapsigargin. The Ca2+ entry induced
by UTP was partially attenuated by the receptor-operated
Ca2+ channel blocker SK&F96365 and by the voltage-dependent
Ca2+ channel blocker verapamil. P2
receptor antagonists suramin and, at higher concentrations,
pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid reduced the
effect of UTP.
Conclusions The results are the first demonstration that nucleotides activate G proteincoupled P2u receptors to mobilize [Ca2+]i in rat basilar smooth muscle cells.
Key Words: rats nucleotides muscle, smooth
| Introduction |
|---|
|
|
|---|
There is a widespread appreciation for the potent and diverse interactions of extracellular nucleotides with various body systems. Extracellular nucleotides influence neurotransmission, inflammatory and immune responses, platelet aggregation and secretion, and pulmonary and cardiac functions.9 Extracellular nucleotides play an important role in the regulation of vascular tone, including cerebral arteries,7 8 by activation of P2 receptors. Subtypes of P2 receptors have been classified by numerous studies in peripheral arteries9 ; however, little information is available for P2 receptor subtypes and their Ca2+ mobilization pathways in major cerebral smooth muscle cells. Using [Ca2+]i microfluorimetry, we found that P2u receptors mediated the effect of nucleotides on [Ca2+]i in rat basilar smooth muscle cells.
| Materials and Methods |
|---|
|
|
|---|
[Ca2+]i Microfluorimetry
The buffer solution for [Ca2+]i
measurement was (in mmol/L): 145 NaCl, 2 CaCl2,
3 KCl, 1 MgCl2, 10 HEPES, and 10 glucose, and the pH was
adjusted to 7.4 with NaOH. Cells were loaded with the
fluorescence indicator fura 2-AM (3 µmol/L) for
30 minutes at room temperature in the extracellular buffer
solution.7 10 After loading, cells were rinsed and the
coverslips were then placed in the bottom of a Plexiglas perfusion
chamber (volume approximately 600 µL) with two openings at each end
for perfusion and aspiration. Cells were perfused for 20 minutes before
the experiment to allow deesterification of the dye.
Digital [Ca2+]i imaging was performed by video microfluorimetry using an intensified charge-coupled device (CCD) camera (Hamamatsu) coupled to a Nikon Diaphot microscope (40x Fluor objective, Nikon Inc) and software (Universal Imaging Corp) on a 486 personal computer. Sample illumination was supplied by a 150 W xenon arc lamp, and excitation wavelengths were selected by computer control of a filter wheel. Fluorescence imaging was obtained with alternating excitation wavelengths of 340 and 380 nm, and an emission wavelength of 510 nm through the CCD camera. Typically 4 to 8 frames at each wavelength were averaged to produce ratio images. Data from regions of interest were displayed in real time and logged to hard disk. Background fluorescence obtained from a cell-free position of the same slip was subtracted from all recordings before calculation of the 340/380 ratio. EGTA (0.5 mmol/L) was included in all experiments using a Ca2+-free extracellular buffer.
Subsequent analysis converted the ratio to the [Ca2+]i according to the following calibration method. Standardized chelated Ca2+-free and high-Ca2+ buffers (Molecular Probes) were mixed in 10 varying proportions, with 2 µmol/Lfura 2 salt added, covering the range of Ca2+ from 7.9 to 2860 nmol/L. Ratio values for 340 nm to 380 nm fluorescence were determined from droplets of these standard mixtures of known Ca2+, with the objective focused approximately 20 µm above the glass coverslip and with background from a fura 2free solution. The relationship of the Ca2+ to the 340 nmto380 nm ratio was fitted by an iterative regression to the predicted relationship for fura 211 to determine Rmin, Rmax, and the apparent Kd. These values were then used to convert ratio data to approximate [Ca2+]i values.7 10
Reagents
Fura 2-acetoxymethyl ester (fura 2-AM) was purchased from
Molecular Probes; SK&F96365, suramin sodium salt, and thapsigargin from
Calbiochem; PPADS from Research Biochemicals; and ATP, ADP, AMP,
adenosine, UTP, UDP, UMP, uridine, GTP, TTP, ITP, CTP, ATP
S,
NCDC, pertussis toxin, cell isolation enzymes, and all other chemicals
from Sigma Chemical Co.
Data Analysis
Data are expressed as mean±SD. Statistical differences between
the control groups and other groups were compared using one-way ANOVA
and then Tukey-Kramer multiple comparisons procedure (95% lower and
upper confidence interval) if significant variance was found. A value
of P<.05 was considered statistically significant. In all
figures drug exposures and solution changes are indicated by the
horizontal lines.
| Results |
|---|
|
|
|---|
General Effects of Nucleotides
Application of ATP, UTP, TTP (100 nmol/L to 1
mmol/L), and at higher concentrations CTP, GTP, or ITP (0.1 to
1 mmol/L), produced a transient
[Ca2+]i peak followed by a steady-state
[Ca2+]i plateau that decreased slowly to a
level slightly above the resting level after 20-minute application in
rat basilar smooth muscle cells (examples are shown in Fig 2A
and B of
5-minute application of UTP). In Ca2+-free buffer solution,
ATP, UTP, and TTP produced a transient
[Ca2+]i peak that returned to the baseline
rapidly without a plateau phase, which suggests that the
[Ca2+]i peak was Ca2+ released
from intracellular stores and that the
[Ca2+]i plateau was Ca2+ that
entered from the extracellular space (see Fig 3A
). The effect of these
nucleotides on [Ca2+]i was
dose-dependent, completely reversible by washout, and repeatable.
|
|
Effects of Different Nucleotides
We tested the effect of different nucleotides to raise
[Ca2+]i in cells. Each dose of each
nucleotides was tested separately as described above, and
the peak and plateau [Ca2+]i responses to
nucleotides both were used for the calculation. The maximum
responses to ATP
S, UTP, UDP, ATP, TTP, and ITP were obtained, and
the ED50 values for these nucleotides were
calculated from nonlinear regression. The log10
ED50 values were ATP
S 6.5, UTP 6.1, UDP 5.6, ATP 5.8,
TTP 5.4, and ITP 4.6, respectively. Since the responses to CTP and GTP
failed to reach the maximum and since UMP and uridine failed to produce
marked effects, their ED50 values were not calculated. Fig 1A
and B shows the dose-dependent
elevation of [Ca2+]i to different
nucleotides. The potency of nucleotides to
raise [Ca2+]i was UTP (selective agonist for
P2u receptors)
ATP (selective agonist for P2
receptors)
TTP (Fig 1A
, peak responses; 1B, plateau responses). GTP
and CTP failed to produce marked response at concentrations below
1 mmol/L. Fig 1C
(peak responses) and 1D (plateau
responses) shows the potency of ATP
S and uracil
nucleotides to raise [Ca2+]i.
ATP
S (selective agonist for P2u receptors)
UTP
UDP.
UMP and uridine failed to induce any marked response. Since UTP, UDP,
and ATP
S are selective agonists for P2u but not for
P2x or P2y receptors and since UTP,
UDP, and ATP
S were equally (or more) potent to ATP, these studies
indicate the predominance of P2u receptors in rat basilar
smooth muscle cells.
|
Signal Transduction Pathways of P2u Receptors
Since UTP was one of the most potent agonists among these
nucleotides, we used UTP as the agonist to study signal
transduction pathways in rat basilar smooth muscle cells. The
[Ca2+]i responses to UTP (100
µmol/L) in cells pretreated with pertussis toxin (1200
ng/mL) for 10 hours12 were compared with those of
control cells. As shown in Fig 2A
and C,
pretreatment with pertussis toxin (Fig 2A
, right) markedly reduced the
[Ca2+]i responses to UTP. The PLC
inhibitor NCDC (10 µmol/L)13 was
tested and found, after 15 minutes' incubation with cells, to abolish
the [Ca2+]i responses to UTP (100
µmol/L, Fig 2B
and C).
Since activation of PLC produces inositol 1,4,5-triphosphate
(IP3), which releases Ca2+ from internal
stores, we tested the effect of UTP on thapsigargin-sensitive
Ca2+ stores. UTP (100 µmol/L) produced a
transient [Ca2+]i peak response without
plateau phase in Ca2+-free external solution (Fig 3A
, left)
. In the absence of external
Ca2+, thapsigargin (100 nmol/L), a well-known
Ca2+-pump inhibitor, produced a transient
[Ca2+]i rise (leak) that lasted about 5 to 7
minutes before falling to a level similar to the resting level (Fig 3A
, right). The following application of UTP (100 µmol/L), in
the presence of thapsigargin, failed to induce any marked
[Ca2+]i elevation (Fig 3A
, right).
Thapsigargin produced a prolonged [Ca2+]i
elevation in the presence of external Ca2+ in our previous
studies.14 [Ca2+]i peak and
plateau responses induced by UTP in the presence and absence of
external Ca2+ and the inhibitory effect of
thapsigargin on UTP-induced [Ca2+]i elevation
in the absence of external Ca2+ are compared in Fig 3B
.
The pathways for Ca2+ entry activated by UTP were
studied by using the receptor-operated Ca2+ influx blocker
SK&F96365 and the voltage-dependent Ca2+ channel blocker
verapamil. SK&F96365 (5 µmol/L; Fig 4A
, left) markedly and
verapamil (1 µmol/L, Fig 4A
, right) partially
reduced the [Ca2+]i plateau phase induced by
UTP without significant effect on the [Ca2+]i
peak. Lanthanum (100 µmol/L, Fig 4B
), an inorganic
Ca2+ channel blocker, abolished both peak and plateau
responses induced by UTP, consistent with our previous report
that lanthanum completely abolishes the
[Ca2+]i response to ATP-containing
erythrocyte lysate.7 The effects of Ca2+ entry
blockers are summarized in Fig 4B
.
|
P2-Purinoceptor Antagonists
[Ca2+]i response to UTP was further
examined using P2 receptor antagonists.
Suramin, a selective P2 receptor antagonist,
and PPADS, a selective P2x receptor
antagonist,15 were incubated with cells for 5
minutes before UTP (100 µmol/L) was applied (Fig 5A
). PPADS at 10 µmol/L
failed to reduce the effect of UTP (Fig 5B
), the concentration that
inhibited the effect of ATP on P2x
receptors.15 PPADS at 30 µmol/L partially
reduced the plateau but not the peak [Ca2+]i
response induced by UTP. At higher concentration, PPADS (100
µmol/L) markedly reduced both the peak and plateau responses.
Pre-incubation with suramin (1 µmol/L) significantly
reduced both the peak and plateau responses induced by UTP (Fig 5C
).
However, increasing the suramin concentration to 100
µmol/L failed to further reduce the
[Ca2+]i response to UTP (Fig 5C
).
|
| Discussion |
|---|
|
|
|---|
S, UTP and UDP
produced [Ca2+]i responses similar to those
of ATP, consistent with our previous report that
P2u receptors mediate effects of nucleotides in
rat basilar artery smooth muscle cells, since a selective agonist of
P2x receptor
ß-Methylene-ATP and selective
agonist of P2y receptor 2-Methylthio-ATP failed to markedly
raise [Ca2+]i.7 Using pertussis
toxin, NCDC, and thapsigargin, we have shown that the P2u
receptor in these cells was coupled to G protein and, by activation of
PLC, released Ca2+ from intracellular
thapsigargin-sensitive stores. A similar mechanism of Ca2+
mobilization by activation of P2u receptors has been
reported previously in other tissues.9 The partial
retention of the [Ca2+]i response to UTP
after 10 hours of treatment with a high concentration of pertussis
toxin (1200 ng/mL) indicates that other G proteins that are not
sensitive to pertussis toxin may also be involved in the UTP-induced
[Ca2+]i response. It has been established
that PLC can be activated either by an
-subunit of the
pertussis toxin-insensitive Gq/GII family or
the ß
-dimer of the pertussis toxinsensitive
Gi2.16 NCDC at 10 µmol/L
completely abolished the [Ca2+]i response to
UTP, indicating UTP-induced intracellular Ca2+ mobilization
was mediated by activation of PLC in these cells. Furthermore, we have
demonstrated that 1 µmol/L suramin inhibited the
[Ca2+]i response to UTP, consistent
with our previous finding that suramin reduced the effect of
ATP-containing erythrocyte lysate on [Ca2+]i
in rat basilar smooth muscle cells7 and contraction in dog
basilar artery.8 PPADS, a selective antagonist
for P2x receptors, failed to significantly
reduce the effect of UTP at concentrations that blocked the effect of
P2x receptors in other tissues.15
The inhibitory effect of PPADS at 100
µmol/Lcould be due to nonspecific effects. We have observed
previously that PPADS possessed limited effects on either
[Ca2+]i7 or contraction produced
by ATP-containing erythrocyte lysate.8 Whether the effect
of PPADS at 30 µmol/L that significantly reduced the
plateau but not the peak [Ca2+]i response is
due to its blockade of P2x receptors, which may
contribute partially to the plateau phase, needs further
investigation. It has been established that P2u (or P2y217 ) receptors are G proteincoupled receptors and that signal transduction is mediated by the receptorG proteinPLC-IP3 system, which mobilizes internal Ca2+ stores.9 Store depletion triggers Ca2+ entry via voltage-independent Ca2+ pathways, possibly by diffusible chemical messengers.18 Ca2+ entry through voltage-dependent Ca2+ channels may also partially contribute to UTP-induced [Ca2+]i elevation.9 We have demonstrated that both receptor-operated Ca2+ influx inhibitor SK&F96365 and voltage-dependent Ca2+ channel blocker verapamil markedly reduced the Ca2+ entry induced by UTP, consistent with other reports using peripheral vasculature.9 SK&F96365 but not verapamil significantly reduced the Ca2+ entry induced by erythrocyte lysate in cultured endothelial cells in our previous study.10 Lanthanum completely abolished both peak and plateau [Ca2+]i responses to UTP in this study, consistent with our previous results that lanthanum abolished [Ca2+]i response to erythrocyte lysate.7 The mechanism by which lanthanum blocks both peak and plateau [Ca2+]i responses is not clear but may be explained by its multiple actions against Ca2+ entry via membrane Ca2+ channels, Na+/Ca2+ exchangers, and Ca2+-ATPase pumps.7 Cytosolic Ca2+ binds to calmodulin, and the Ca2+-calmodulin complex subsequently activates myosin light chain kinase that phosphorylates the light chain of myosin, thus activating the Mg2+-ATPase activity, which promotes the formation of myosin-actin crossbridges.19 Several recent investigations indicated that ATP and UTP elevate [Ca2+]i and contract cerebral arteries and that these effects of ATP and UTP were prevented by P2 receptor antagonists.7 8 20 21 22 23 24 The P2u receptor is believed to be activated by both ATP and UTP,9 although some studies have suggested the existence of two different receptors for ATP and UTP.23 Cross-desensitization would be a better way to distinguish these two types of receptors.25 In our preliminary studies, ATP (0.1 to 1 mmol/L, 5 minutes) failed to produce additional [Ca2+]i response in the presence of UTP (0.1 to 1 mmol/L, pretreated with cells for 1 or 5 minutes), and UTP failed to produce additional [Ca2+]i response in the presence of ATP, indicating that possibly only one type of receptor mediated the effect of nucleotides in rat basilar smooth muscle cells.
Cytoplasmic ATP may be released after cell lysis or selective permeabilization of the plasma membrane. This permeabilization can occur in various types of cells, including the smooth muscle cells,9 in the absence of irreversible damage such as hypoxia. Exocytosis of secretory granules such as platelet-dense bodies (>600 mmol/L ATP) also contributes to the presence of extracellular ATP, as well as other nucleotides such as ADP (±400 mmol/L), GTP, and UTP.26 After aneurysmal SAH, ATP, which could be released from blood clots, would contact major cerebral arteries from the adventitia side, activate P2x and P2u receptors in smooth muscle cells, and may produce vasospasm.7 8 27 Since a high level of ATP, ADP, and UTP exists in blood cells,26 these blood cells may play an important role in the pathogenesis of vasospasm.7 28 ATP and ADP produce contraction by activation of P2 receptors or by releasing vasocontractile agents such as eicosanoids from cerebral endothelial cells.21 22 29 Presumably, these contractile actions of blood cells during vasospasm may be further amplified by SAH-induced endothelial dysfunction. Endothelial degeneration and disruption attenuated the production of prostacyclin and nitric oxide and attenuated the ADP-induced relaxation.28 However, damaging endothelial cells with oxyhemoglobin enhanced the production of endothelins.14 Oxyhemoglobin in erythrocyte lysate, which chelates nitric oxide, may also potentiate the contractile effect of ATP-containing erythrocyte lysate.
The ability of UTP, UDP, ATP, and TTP to elevate
[Ca2+]i indicates that multiple
nucleotides may have vasoactive effects in cerebral
vasculature. The vasoconstrictive properties of UTP and
its possible role in chronic cerebral vasospasm have been investigated.
UTP induced long-lasting contractions of isolated human brain arteries
up to 20 to 24 hours.30 Both UTP and UDP produced
vasoconstriction of canine cerebral arteries and intracisternal
application of UTP produced cerebral vasospasm in dogs.20
The vasoconstrictive effect of different
nucleotides was tested in rabbit basilar artery. The rank
order of potency of the pyrimidine nucleotides was
UTP=UDPUMP=CTP; that of the purine nucleotides was
ATP
S>AMP-PNP>ATP>
ADP>2-methylthio-ATP=
,ß-methylene-ATP=ß,
-methylthio-ATP.23
UTP produced much stronger contractions than ATP in canine basilar
arteries.8 We have obtained a similar effect for
nucleotides to raise [Ca2+]i in
rat basilar smooth muscle cells in this study. Since UTP, UDP, and
ATP
S are all selective agonists for P2u receptors, these
studies indicate a predominance of P2u receptors in
cerebral arteries. ATP, however, may be a primary candidate for
eliciting vascular responses such as vasospasm after SAH due to its
abundance relative to the other nucleotides inside all
cells and especially in red blood cells and
platelets.9 ATP produced
endothelium-dependent contraction by releasing
endothelium-derived contracting factors, possibly
thromboxane A2, and
endothelium-independent relaxation by activation of
P1 receptors in canine basilar artery.21 The
endothelium-independent and
endothelium-dependent contractions induced by ATP were
mediated by P2x and P2y receptors
in canine basilar arteries, respectively.22 In cannulated
rabbit basilar artery, application of ATP or UTP from adventitia side
caused contraction but not relaxation.23 Application of
ATP directly into canine basilar arteries in the canine model of
vasospasm, in an attempt to relieve vasospasm, further aggravated
vasospasm and caused disruption of
endothelium.31 Adenine
nucleotides were detected in erythrocyte lysate and were
suggested to mediate the effect of erythrocyte lysate on
[Ca2+]i and contraction in cerebral
arteries.7 8
There are challenges to the hypothesis that UTP and ATP mediate the smooth muscle contraction observed in vasospasm. Extracellular ectonucleotidases rapidly metabolize ATP and other nucleotides.9 To elicit vasoconstriction, the release of UTP or ATP must overcome degradation by extracellular nucleotides hydrolyzing enzymes. However, subsequent metabolism of ATP to di- and monophosphates and adenosine by ectonucleotidases may enhance the effects of ATP.32 Future studies to determine the time course of the concentrations of nucleotides in cerebrospinal fluid and blood clots during vasospasm may provide answers to these questions.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received March 7, 1997; revision received June 10, 1997; accepted June 11, 1997.
| References |
|---|
|
|
|---|
2. Kiwak KJ, Heros RC. Cerebral vasospasm after subarachnoid hemorrhage. Trends Neurol Sci. 1987;10:89-92.
3. Bevan JA, Bevan RD. Arterial wall changes in chronic cerebrovasospasm: in vitro and in vivo pharmacological evidence. Ann Rev Pharmacol Toxicol. 1988;28:311-329.[Medline] [Order article via Infotrieve]
4. Mayberg MR, Okada T, Bark DH. The significance of morphological changes in cerebral arteries after subarachnoid hemorrhage. J Neurosurg. 1990;72:624-633.
5. Aoki T, Takenaka K, Suzuki S, Kassell N, Sagher O, Lee K. The role of hemolysate in the facilitation of oxyhemoglobin-induced contraction in rabbit basilar arteries. J Neurosurg. 1994;81:261-266.[Medline] [Order article via Infotrieve]
6. Cosentino F, Katusic ZS. Does endothelin-1 play a role in the pathogenesis of cerebral vasospasm? Stroke. 1994;25:904-908.[Abstract]
7.
Zhang H, Weir B, Marton L, Macdonald RL, Bindokas V,
Miller R, Brorson J. Mechanisms of hemolysate-induced calcium
elevation in cerebral smooth muscle cells. Am J
Physiol. 1995;269:H1874-H1890.
8. Sima B, Macdonald RL, Marton LS, Weir B, Zhang J. Effect of P2-purinoceptor antagonists on hemolysate- and ATP-induced contractions of dog basilar artery in vitro. Neurosurgery. 1996;39:815-822.[Medline] [Order article via Infotrieve]
9.
Dubyak GR, El-Moatassim C. Signal transduction
via P2-purinergic receptors for extracellular ATP and other
nucleotides. Am J Physiol. 1993;265:C577-C606.
10.
Zhang H, Weir B, Macdonald RL, Marton L, Solenski N,
Kwan J, Lee K. Mechanisms of [Ca2+]i
elevation induced by erythrocyte components in
endothelial cells. J Pharmacol Exp
Ther. 1996;277:1501-1509.
11.
Grynkiewicz G, Poenie M, Tsien R. A new
generation of Ca2+ indicators with greatly improved
fluorescence properties. J Biol Chem. 1985;260:3440-3450.
12.
Sjölander A, Grönroos E, Hammarström
S, Andersson T. Leukotriene D4 and
E4 induce transmembrane signaling in human epithelial
cells. J Biol Chem. 1990;265:20976-20981.
13.
Yuan Y, Granger HJ, Zawieja DC, DeFily DV, Chilian
WM. Histamine increases venular permeability via a phospholipase
C-NO synthase-guanylate cyclase cascade.
Am J Physiol. 1993;264:H1734-H1739.
14. Macdonald RL, Wang X, Zhang J, Marton L. Molecular changes with subarachnoid hemorrhage and vasospasm. In: Raffel C, Harsh G, eds. The Molecular Biology of Neurosurgical Disease. Baltimore, Md: Williams & Wilkins; 1997:278-293.
15. Ziganshin AU, Hoyle CH, Bo X, Lambercht G, Mutschler E, Baumert HG, Burnstock G. PPADS selectively antagonizes P2x-purinoceptor-mediated responses in the rabbit urinary bladder. Br J Pharmacol. 1993;110:1491-1495.[Medline] [Order article via Infotrieve]
16.
Clapham DE, Neer EJ. New roles for G-protein
ß
dimers in transmembrane signaling. Nature. 1993;365:403-406.[Medline]
[Order article via Infotrieve]
17. Barnard EA, Burnstock G, Webb TE. G protein-coupled receptors for ATP and other nucleotides: a new receptor family. Trends Pharmacol Sci. 1994;15:67-70.[Medline] [Order article via Infotrieve]
18. Fasolato C, Innocenti B, Pozzan T. Receptor-activated Ca2+ influx: how many mechanisms for how many channels? Trends Pharmacol Sci. 1994;15:77-83.[Medline] [Order article via Infotrieve]
19. Missiaen L, De Smedt H, Droogmans G, Himpens B, Casteels R. Calcium ion homeostasis in smooth muscle. Pharmacol Ther. 1992;56:191-231.[Medline] [Order article via Infotrieve]
20.
Shirasawa Y, White RP, Robertson JT. Mechanisms
of the contractile effect induced by uridine 5-triphosphate in canine
cerebral arteries. Stroke. 1983;14:347-354.
21.
Shirahase H, Usui H, Manabe K, Kurahashi K, Fukiwara
M. Endothelium-dependent contraction and
-independent relaxation induced by adenine nucleotides and
nucleoside in the canine bisilar artery. J Pharmacol
Exp Ther. 1988;247:1152-1157.
22. Shirahase H, Usui H, Shimaji H, Kurahashi K, Fukiwara M. Endothelium-independent and endothelium-dependent contractions mediated by P2x- and P2y-purinoceptors in canine basilar arteries. J Pharmacol Exp Ther. 1991;258:683-688.
23. Von Khgelgen I, Starke K. Evidence for two separate vaso-constriction-mediating nucleotide receptors, both distinct from the P2x-receptors, in rabbit basilar artery: a receptor for pyrimidine nucleotides and a receptor for purine nucleotides. Naunyn Schmiedeberg's Arch Pharmacol. 1990;341:538-546.[Medline] [Order article via Infotrieve]
24. Ikeuchi Y, Nishizaki T. ATP activates the potassium channel and enhances cytosolic Ca2+ release via a P2y purinoceptor linked to pertussis toxin-insensitive G-protein in brain artery endothelial cells. Biochem Biophys Res Commun. 1995;215:1022-1028.[Medline] [Order article via Infotrieve]
25. Yang S, Buxton ILO, Probert CB, Talbot JN, Bradley ME. Evidence for a discrete UTP receptor in cardiac endothelial cells. Br J Pharmacol. 1996;117:1572-1578.[Medline] [Order article via Infotrieve]
26. Motte S, Communi D, Pirotton S, Boeynaems J-M. Involvement of multiple receptors in the actions of extracellular ATP: the example of vascular endothelial cells. Int J Biochem Cell Biol. 1995;27:1-7.[Medline] [Order article via Infotrieve]
27.
Ralevic V, Burnstock G. Roles of
P2-purinoceptors in the cardiovascular
system. Circulation. 1991;84:1-14.
28. Akopov S, Sercombe R, Seylaz J. Cerebrovascular reactivity: role of endothelium/platelet/leukocyte interactions. Cerebrovasc Brain Metab Rev. 1996;8:11-94.[Medline] [Order article via Infotrieve]
29.
Dominiczak AF, Quilley J, Bohr EF. Contraction
and relaxation of rat aorta in response to ATP. Am J
Physiol. 1991;261:H243-H251.
30.
Urquilla PR. Prolonged contraction of isolated
human and canine cerebral arteries induced by uridine
5'-triphosphate. Stroke. 1978;9:133-136.
31. Haciyakupoglu S, Kaya M, Cetinalp E, Yucesoy A. Effect of prostacyclin and adenosine triphosphate on vasospasm of canine basilar artery. Surg Neurol. 1985;24:126-140.[Medline] [Order article via Infotrieve]
32.
Gerwins P, Fredholm BB. ATP and its metabolite
adenosine act synergistically to mobilize intracellular calcium
via the formation of inositol 1,4,5-trisphostate in a smooth muscle
cell line. J Biol Chem. 1992;267:16081-16087.
This article has been cited by other articles:
![]() |
J. Nilsson, L. M. Nilsson, Y.-W. Chen, J. D. Molkentin, D. Erlinge, and M. F. Gomez High Glucose Activates Nuclear Factor of Activated T Cells in Native Vascular Smooth Muscle Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 794 - 800. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. del Valle-Rodriguez, E. Calderon, M. Ruiz, A. Ordonez, J. Lopez-Barneo, and J. Urena Metabotropic Ca2+ channel-induced Ca2+ release and ATP-dependent facilitation of arterial myocyte contraction. PNAS, March 14, 2006; 103(11): 4316 - 4321. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Miyagi and J. H. Zhang {alpha},{beta}-Methylene ATP enhances P2Y4 contraction of rabbit basilar artery Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1546 - H1551. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Miao, Y. Dai, and J. Zhang Mechanism of RhoA/Rho kinase activation in endothelin-1- induced contraction in rabbit basilar artery Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H983 - H989. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Welsh and J. E. Brayden Mechanisms of coronary artery depolarization by uridine triphosphate Am J Physiol Heart Circ Physiol, June 1, 2001; 280(6): H2545 - H2553. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Carpenter, L. Miao, Y. Miyagi, E. Bengten, J. H. Zhang, and J. P. Muizelaar Altered Expression of P2 Receptor mRNAs in the Basilar Artery in a Rat Double Hemorrhage Model Editorial Comment Stroke, February 1, 2001; 32(2): 516 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Jaggar and M. T. Nelson Differential regulation of Ca2+ sparks and Ca2+ waves by UTP in rat cerebral artery smooth muscle cells Am J Physiol Cell Physiol, November 1, 2000; 279(5): C1528 - C1539. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Aoki, A. Y. Zubkov, A. D. Parent, J. H. Zhang, and R. L. Macdonald Mechanism of ATP-Induced [Ca2+]i Mobilization in Rat Basilar Smooth Muscle Cells Editorial Comment Stroke, June 1, 2000; 31(6): 1377 - 1385. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |